New hope for tough leukemia: drug combo trial targets older and relapsed patients

NCT ID NCT03319901

First seen Jun 02, 2026 · Last updated Jun 14, 2026 · Updated 2 times

Summary

This study tests whether adding the drug venetoclax to standard chemotherapy can help treat acute lymphoblastic leukemia (ALL). It includes older adults (60+) with newly diagnosed ALL and adults (18+) whose leukemia has come back or not responded to treatment. The goal is to find the safest dose and see how well the combination works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • Intermountain LDS Hospital

    Salt Lake City, Utah, 84143, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

Conditions

Explore the condition pages connected to this study.

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.